Table 3.

Subgroup analyses of the relationships between CD133 ovexpression and overall survival or progression-free-survival

Comparison variables	Overall survival			Progression-free survival
	Number of studies, Heterogeneity (I2 statistics; %)	HR 95 % CI, P value	Interaction, P value	Number of studies, Heterogeneity (I2 statistics; %)	HR 95 % CI, P value	Interaction, P value
Total	11 (77.8)	1.69 (1.16–2.47), 0.006	NA	8 (68.2)	1.64 (1.12–2.39), 0.010	NA
Origin country
Europe	8 (81.0)	1.63 (1.03–2.61), 0.039	0.030	6 (76.5)	1.74 (1.06–2.83), 0.027	0.579
Asian	3 (42.5)	1.85 (1.02–3.35), 0.044		2 (0.0)	1.37 (0.86–2.18), 0.188
Sample size
>50	4 (77.4)	1.45 (0.91–2.31), 0.116	0.000	3 (0.0)	1.37 (1.01–1.73), 0.009	0.092
≤50	7 (67.6)	1.94 (1.07–3.54), 0.030		5 (77.0)	1.99 (0.94–4.22), 0.073
Follow up period
1,>media 12months	4 (74.1)	2.48 (1.13–5.45), 0.024	0.000	3 (86.7)	2.64 (0.98–7.11), 0.054	0.060
2,≤media 12months	3 (43.0)	0.90 (0.54–1.49), 0.678		3 (0.0)	1.12 (0.79–1.57), 0.530
3,No Referreed	4 (0)	2.11 (1.52–2.93), 0.000		2 (0.0)	1.64 (1.19–2.27), 0.003
Median/mean age y
Referred	6 (0.0)	1.85 (1.45–2.37), 0.000	0.000	3 (0.0)	1.59 (1.24–2.04), 0.000	0.713
No Referred	5 (79.8)	1.57 (0.70–3.55), 0.274		5 (80.8)	1.79 (0.81–3.97), 0.153
Test method
IHC	5 (64.8)	2.16 (1.25–3.73), 0.006	0.000	4 (80.9)	2.25 (1.11–4.58), 0.025	0.122
Others	6 (71.2)	1.37 (0.85–2.22), 0.202		4 (20.4)	1.31 (0.93–1.84), 0.122
Cut‑off level
1:median	4 (61.4)	1.09 (0.66–1.79) 0.748	0.000	3 (0.0)	1.12 (0.79–1.57), 0.530	0.024
2:others	7 (51.3)	2.17 (1.44–3.27), 0.000		5 (74.5)	2.07 (1.25–3.43), 0.005
WHO grade
IV	8 (76.3)	1.73 (1.20–2.50), 0.004	0.915	5 (0.00)	1.46 (1.19–1.80), 0.000	0.143
II–III	3 (87.0)	2.38 (0.30–18.82), 0.411		3 (88.1)	2.17 (0.42–11.28), 0.355